Video Interview: Roche Doubles Down On Immuno-Oncology Trial Collaborations
This article was originally published in Scrip
Roche partnering exec Jason Coloma explains his company's approach to developing the next wave of immuno-oncology therapies, through collaborations. In the fast-paced, high value world of immuno-oncology development, the number of potential combinations of therapies, including doublet and triplet regimens, is enormous.Recognizing that means you won't have everything in-house and will need to establish external collaborations with a wide range companies, Coloma explains to Emily Hayes, senior editor at Scrip's sister publication, "The Pink Sheet".
In 2015, Roche set up a cancer immunotherapy committee to evaluate the many proposals for novel combinations, says Coloma, head of oncology and cancer immunotherapy partnering at Roche. The efforts translated into a variety of collaborations last year, with more on the way for 2016. There is a vast array of potential targets and it's still unclear which therapies will make the best partners for PD-1/L1 checkpoint inhibitors, which are at the forefront of development. It's safe to say the jury is still out as the data are being generated for particular indications, Coloma explains.
This interview took place during EBD Group's Biotech Showcase in San Francisco, Jan. 11-13, 2016. Further panel discussions and interviews can be viewed here.